FROM:
Cell Growth & Differentiation 1996 (Oct); 7 (10): 1345–1351
Peterson G, Barnes S
Department of Pharmacology and Toxicology,
University of Alabama at Birmingham 35294, USA
Genistein is a naturally occurring dietary protein tyrosine
kinase (PTK) inhibitor that is hypothesized to be responsible for
the lower rate of breast cancer observed in Asian women consuming
soy. Although genistein is a potent in vitro PTK inhibitor, its
mechanism of action in vivo is not known. In vivo, breast cancer
growth is regulated by estrogens and peptide growth factors, such
as epidermal growth factor (EGF), the receptor of which has
intrinsic PTK activity.
Therefore, genistein may block mammary epithelial cell growth by
interfering with signal transduction events stimulated by
estradiol or growth factors. The effect of genistein, related
isoflavones, and other tyrosine kinase inhibitors on fetal bovine
serum-, estradiol-, and EGF-stimulated cell growth and signal
transduction pathways was examined in five human breast cancer
cell lines. Genistein inhibited the growth of these cells by
each of the growth stimuli with IC50 values ranging from 2.6 to
over 20 micrograms/ml.
Growth inhibition by genistein was cytostatic and reversible at
IC50 concentrations. Related isoflavones were less potent growth
inhibitors than genistein, whereas the synthetic PTK inhibitor
tyrphostin A25 was an equally potent growth inhibitor. The
mechanism of genistein growth inhibition in human breast cancer
cells did not depend on the presence of functional estrogen
receptor signaling pathways or on inhibition of EGF-receptor PTK
activity. Furthermore, genistein (< or = 20 micrograms/ml) did
not decrease constitutive or EGF-induced tyrosine phosphorylation
as determined by Western blotting with antiphosphotyrosine
antibodies.
These data suggest that although genistein inhibits the growth of
breast cancer cells in culture, it does so without gross
inhibition of PTK activity.